Skip to main content

6 Result(s)

within V Lagarde Remove this filter

and

  1. No Access

    Article

    From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome

    S Bouchet, S Dulucq, J-M Pasquet, V Lagarde, M Molimard, F-X Mahon in Leukemia (2013)

  2. Article

    Open Access

    Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence

    Imatinib, the anti-Abl tyrosine kinase inhibitor used as first-line therapy in chronic myeloid leukemia (CML), eliminates CML cells mainly by apoptosis and induces autophagy. Analysis of imatinib-treated K562 ...

    C Drullion, C Trégoat, V Lagarde, S Tan, R Gioia, M Priault… in Cell Death & Disease (2012)

    Download PDF (750 KB) View Article

  3. No Access

    Article

    Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia

    Imatinib is an effective therapy for chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the expression of the recombinant oncoprotein Bcr-Abl. In this investigation, we studied an i...

    M Pocaly, V Lagarde, G Etienne, J-A Ribeil, S Claverol, M Bonneu… in Leukemia (2007)

  4. No Access

    Article

    An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

    T Leguay, V Desplat, V Lagarde, G Marit, J Reiffers, F-X Mahon in Leukemia (2005)

  5. No Access

    Article

    Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

    Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). The drug shows great efficacy in ...

    AJ Tip**, FX Mahon, G Zafirides, V Lagarde, JM Goldman, JV Melo in Leukemia (2002)

  6. No Access

    Article

    Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571

    The leukemogenic property of BCR-ABL in chronic myeloid leukemia (CML) is critically dependent on its protein tyrosine kinase activity. STI571 inhibits the BCR-ABL kinase activity, the growth and the viability...

    R Tabrizi, FX Mahon, P Cony Makhoul, V Lagarde, F Lacombe, P Berthaud, JV Melo… in Leukemia (2002)